Stimulation of serotonin2C receptors elicits abnormal oral movements by acting on pathways other than the sensorimotor one in the rat basal ganglia.
Serotonin2C (5-HT(2C)) receptors act in the basal ganglia, a group of sub-cortical structures involved in motor behavior, where they are thought to modulate oral activity and participate in iatrogenic motor side-effects in Parkinson's disease and Schizophrenia. Whether abnormal movements initiated by 5-HT(2C) receptors are directly consequent to dysfunctions of the motor circuit is uncertain. In the present study, we combined behavioral, immunohistochemical and extracellular single-cell recordings approaches in rats to investigate the effect of the 5-HT(2C) agonist Ro-60-0175 respectively on orofacial dyskinesia, the expression of the marker of neuronal activity c-Fos in basal ganglia and the electrophysiological activity of substantia nigra pars reticulata (SNr) neuron connected to the orofacial motor cortex (OfMC) or the medial prefrontal cortex (mPFC). The results show that Ro-60-0175 (1 mg/kg) caused bouts of orofacial movements that were suppressed by the 5-HT(2C) antagonist SB-243213 (1 mg/kg). Ro-60-0175 (0.3, 1, 3 mg/kg) dose-dependently enhanced Fos expression in the striatum and the nucleus accumbens. At the highest dose, it enhanced Fos expression in the subthalamic nucleus, the SNr and the entopeduncular nucleus but not in the external globus pallidus. However, the effect of Ro-60-0175 was mainly associated with associative/limbic regions of basal ganglia whereas subregions of basal ganglia corresponding to sensorimotor territories were devoid of Fos labeling. Ro-60-0175 (1-3 mg/kg) did not affect the electrophysiological activity of SNr neurons connected to the OfMC nor their excitatory-inhibitory-excitatory responses to the OfMC electrical stimulation. Conversely, Ro-60-0175 (1 mg/kg) enhanced the late excitatory response of SNr neurons evoked by the mPFC electrical stimulation. These results suggest that oral dyskinesia induced by 5-HT(2C) agonists are not restricted to aberrant signalling in the orofacial motor circuit and demonstrate discrete modifications in associative territories.
Beyeler
A
A
Université de Bordeaux, 33076 Bordeaux Cedex, France; Centre National de la Recherche Scientifique (Unité Mixte de Recherche 5227), 33076 Bordeaux Cedex, France.
Kadiri
N
N
Navailles
S
S
Boujema
M Ben
MB
Gonon
F
F
Moine
C Le
CL
Gross
C
C
De Deurwaerdère
P
P
D000818:Animals; D001479:Basal Ganglia / Q000187:drug effects / Q000503:physiopathology*; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000503:physiopathology*; D004558:Electric Stimulation; D005021:Ethylamines / Q000494:pharmacology* / Q000633:toxicity; D005152:Facial Muscles / Q000503:physiopathology*; D005786:Gene Expression Regulation / Q000187:drug effects; D016762:Genes, fos; D007211:Indoles / Q000494:pharmacology* / Q000633:toxicity; D008297:Male; D009055:Mouth; D009434:Neural Pathways / Q000187:drug effects* / Q000503:physiopathology; D016761:Oncogene Proteins v-fos / Q000096:biosynthesis; D017397:Prefrontal Cortex / Q000187:drug effects / Q000503:physiopathology; D011725:Pyridines / Q000494:pharmacology* / Q000633:toxicity; D051381:Rats; D017207:Rats, Sprague-Dawley; D044405:Receptor, Serotonin, 5-HT2C / Q000187:drug effects / Q000502:physiology*; D017366:Serotonin Receptor Agonists / Q000494:pharmacology* / Q000633:toxicity; D013378:Substantia Nigra / Q000187:drug effects / Q000503:physiopathology
D005021:Ethylamines; D007211:Indoles; D016761:Oncogene Proteins v-fos; D011725:Pyridines; D044405:Receptor, Serotonin, 5-HT2C; C103848:Ro 60-0175; D017366:Serotonin Receptor Agonists; C406343:SB 243213